公开(公告)号：US20090298045A1

公开(公告)日：2009-12-03

申请号：US11568702

申请日：2005-05-05

申请人： Avraham J. Treves ,  Arnon Nagler ,  Hanan Galsky ,  Iris Bar

发明人： Avraham J. Treves ,  Arnon Nagler ,  Hanan Galsky ,  Iris Bar

IPC分类号： A01N1/00 ,  C12N5/06

CPC分类号： C12N5/0647 ,  C12N5/0081

摘要： A method of producing stem/progenitor cells from human or animal origin. A population, from an embryonic, fetal or adult source, preferably from bone marrow, blood, fat, muscle, heart, intestine, kidney, liver, lung, pancreas, skin or neural tissues, that includes stem/progenitor cells, is treated with one or more first cytostatic or cytotoxic agents to which the stem/progenitor cells are less sensitive than the other cells of the population. Preferably, the agent(s) selectively deplete(s) from the population cells that are negative with respect to expressing a transporter gene of the first agent(s) while sparing cells that are positive with respect to expressing that gene. Preferably, the population also is treated with one or more cytokines and/or growth factors.

摘要翻译： 从人或动物来源产生干细胞/祖细胞的方法。 来自胚胎，胎儿或成年来源，优选来自骨髓，血液，脂肪，肌肉，心脏，肠，肾，肝，肺，胰腺，皮肤或神经组织（包括干细胞/祖细胞）的群体用 一种或多种第一细胞抑制剂或细胞毒性剂，其干/祖细胞对其群体的其它细胞敏感性较低。 优选地，所述试剂从相对于表达第一试剂的转运蛋白基因而为阴性的群体细胞中选择性地耗尽，同时保留对于表达该基因是阳性的细胞。 优选地，群体还用一种或多种细胞因子和/或生长因子治疗。

公开(公告)号：USRE39574E1

公开(公告)日：2007-04-17

申请号：US09742993

申请日：2000-12-20

申请人： Mark Pines ,  Israel Vlodavsky ,  Arnon Nagler ,  Hua-Quan Mian

发明人： Mark Pines ,  Israel Vlodavsky ,  Arnon Nagler ,  Hua-Quan Mian

IPC分类号： A61K31/519

CPC分类号： A61K31/517

摘要： The invention provides a composition for attenuating neovascularization and treating malignancies, including a pharmaceutically effective amount of a compound having a formula: wherein: R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and R3 is a member of the group consisting of hydrogen and lower alkenoxy carbonyl; as active ingredient therein, in combination with a pharmaceutically acceptable carrier.

摘要翻译： 本发明提供了用于减毒新生血管形成和治疗恶性肿瘤的组合物，包括药学有效量的具有甲醛的化合物

公开(公告)号：US20060194822A1

公开(公告)日：2006-08-31

申请号：US11262317

申请日：2005-10-28

申请人： Arnon Nagler ,  Israel Vlodavsky ,  Mark Pines ,  Shai Yarkoni

发明人： Arnon Nagler ,  Israel Vlodavsky ,  Mark Pines ,  Shai Yarkoni

IPC分类号： A61K31/517

CPC分类号： A61K31/495

摘要： The present invention relates to compositions containing quinazolinones. More particularly, the present invention relates to a composition for treatment renal fibrosis, comprising as active ingredient a quinazolinone derivative as herein defined. The currently preferred embodiment is halofuginone, which is now show to slow or prevent progression of renal fibrosis in vivo, thereby preventing end-stage renal failure.

摘要翻译： 本发明涉及含有喹唑啉酮的组合物。 更具体地，本发明涉及用于治疗肾纤维化的组合物，其包含作为本文定义的喹唑啉酮衍生物的活性成分。 目前优选的实施方案是卤夫酮，其现在显示为缓慢或预防体内肾纤维化的进展，从而防止终末期肾衰竭。

公开(公告)号：US20130281472A1

公开(公告)日：2013-10-24

申请号：US13782325

申请日：2013-03-01

申请人： Mark Pines ,  Arnon Nagler

发明人： Mark Pines ,  Arnon Nagler

IPC分类号： A61K31/517

CPC分类号： A61K31/517

摘要： A compound in combination with a pharmaceutically acceptable carrier, the compound having a formula: wherein: R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy; and R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and n is either 1 or 2; and pharmaceutically acceptable salts thereof; for use in treatment of or prevention of skeletal muscle fibrosis and/or for inducing skeletal muscle regeneration.

摘要翻译： 化合物与药学上可接受的载体组合，所述化合物具有下式：其中：R 1是氢，卤素，硝基，苯并，低级烷基，苯基和低级烷氧基的成员; R2是由羟基，乙酰氧基和低级烷氧基组成的组的成员; 并且R 3是由氢和低级链烯氧基 - 羰基组成的组的成员; n为1或2; 及其药学上可接受的盐; 用于治疗或预防骨骼肌纤维化和/或用于诱导骨骼肌再生。

公开(公告)号：US20060223108A1

公开(公告)日：2006-10-05

申请号：US11449775

申请日：2006-06-09

申请人： Iris Pecker ,  Israel Vlodavsky ,  Ben Katz ,  Amiram Eldor ,  Menachem Bitan ,  Aaron Polliack ,  Arnon Nagler ,  Zofia Eldor

发明人： Iris Pecker ,  Israel Vlodavsky ,  Ben Katz ,  Amiram Eldor ,  Menachem Bitan ,  Aaron Polliack ,  Arnon Nagler ,  Zofia Eldor

IPC分类号： C12Q1/68 ,  G01N33/574 ,  C12Q1/34

CPC分类号： G01N33/57426 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N2333/924

摘要： Methods and kits for distinguishing between heparanase expressing and heparanase non-expressing hematopoietic cells, particularly useful in distinguishing between different types of differentiated and/or undifferentiated lymphomas and leukemias. The methods and kits are designed to detect heparanase expression, or absence thereof, at the gene, protein and/or protein activity levels.

公开(公告)号：US06420371B1

公开(公告)日：2002-07-16

申请号：US09479660

申请日：2000-01-10

申请人： Mark Pines ,  Israel Vlodavsky ,  Arnon Nagler

发明人： Mark Pines ,  Israel Vlodavsky ,  Arnon Nagler

IPC分类号： A61K31505

CPC分类号： A61K31/517

摘要： The invention provides a composition for attenuating neovascularization and treating malignancies, including a pharmaceutically effective amount of a compound having a formula: wherein: R1 is a number of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy, R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and R3 is a member of the group consisting of hydrogen and lower alkenoxy carbonyl, as active ingredient therein, in combination with a pharmaceutically acceptable carrier.

摘要翻译： 本发明提供一种用于减毒新生血管形成和治疗恶性肿瘤的组合物，包括药学有效量的具有下式的化合物：其中：R1是氢，卤素，硝基，苯并，低级烷基，苯基和低级烷氧基 R2是羟基，乙酰氧基和低级烷氧基的成员，R 3是作为活性成分的氢和低级链烯氧基羰基的组成与药学上可接受的载体的组合。

公开(公告)号：US06211188B1

公开(公告)日：2001-04-03

申请号：US08797702

申请日：1997-02-11

申请人： Mark Pines ,  Arnon Nagler

发明人： Mark Pines ,  Arnon Nagler

IPC分类号： A61K31505

CPC分类号： A61K31/517 ,  Y10S514/863

摘要： An effective treatment for skin disorders characterized by abnormal skin cell behavior, including a pharmaceutically effective amount of Halofuginone. Skin disorders which can be treated include keloids, hypertrophic scars, psoriasis, acne, seborrhea and alopecia. Halofuginone can reduce or eliminate clinical symptoms of these disorders, as well as substantially prevent the formation of keloids and hypertrophic scars.

摘要翻译： 特征在于皮肤细胞行为异常的皮肤病症的有效治疗，包括药学上有效量的卤夫酮。 可以治疗的皮肤疾病包括瘢痕疙瘩，肥大性瘢痕，牛皮癣，痤疮，皮脂溢和脱发。 卤夫酮可以减少或消除这些疾病的临床症状，并且基本上防止瘢痕疙瘩和肥厚性瘢痕的形成。

公开(公告)号：US6028075A

公开(公告)日：2000-02-22

申请号：US797703

申请日：1997-02-11

申请人： Mark Pines ,  Israel Vlodavsky ,  Arnon Nagler ,  Hua-Quan Miao

发明人： Mark Pines ,  Israel Vlodavsky ,  Arnon Nagler ,  Hua-Quan Miao

IPC分类号： C07D401/06 ,  A61K31/517 ,  A61P35/00 ,  A61P43/00 ,  A61K31/505

CPC分类号： A61K31/517

摘要： The invention provides a composition for attenuating neovascularization and treating malignancies, including a pharmaceutically effective amount of a compound having a formula: ##STR1## wherein: R.sub.1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;R.sub.2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, andR.sub.3 is a member of the group consisting of hydrogen and lower alkenoxy carbonyl;as active ingredient therein, in combination with a pharmaceutically acceptable carrier.

摘要翻译： 本发明提供用于减毒新生血管形成和治疗恶性肿瘤的组合物，包括药学有效量的具有下式的化合物：其中：R 1是氢，卤素，硝基，苯并，低级烷基，苯基和低级烷氧基 ; R2是由羟基，乙酰氧基和低级烷氧基组成的组的成员，R3是由氢和低级链烯氧基羰基组成的组的成员; 作为其中的活性成分，与药学上可接受的载体组合。

公开(公告)号：US5041289A

公开(公告)日：1991-08-20

申请号：US120299

申请日：1987-11-13

申请人： Joseph H. Phillips ,  Arnon Nagler ,  Lewis L. Lanier

发明人： Joseph H. Phillips ,  Arnon Nagler ,  Lewis L. Lanier

IPC分类号： C12N5/06 ,  A61K35/14 ,  A61K35/26 ,  A61K35/28 ,  A61P35/00 ,  C12N5/00

CPC分类号： C12N5/0093

摘要： A method is disclosed for removing residual tumor cells from a patient with a neoplastic disorder by treating in vitro cell preparation with lymphokine activated cytotoxic cells.

公开(公告)号：US08410120B2

公开(公告)日：2013-04-02

申请号：US12523954

申请日：2008-01-21

申请人： Mark Pines ,  Arnon Nagler

发明人： Mark Pines ,  Arnon Nagler

IPC分类号： A61K31/505 ,  A61K31/517

CPC分类号： A61K31/517

摘要： A compound in combination with a pharmaceutically acceptable carrier, the compound having a formula: wherein: R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy; and R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and n is either 1 or 2; and pharmaceutically acceptable salts thereof; for use in treatment of or prevention of skeletal muscle fibrosis and/or for inducing skeletal muscle regeneration.